Is it better for industry or for patients to end an early oncology trial? (1)|palmerah.implantgigi.com

Abstract

Background

With an emphasis on oncological clinical trials that were terminated early for benefit, the study's objective is to evaluate the application of interim analysis in RCTs evaluating novel anticancer medications.

Materials and methods

Every published clinical study that used anticancer medications and included an interim analysis that was published during the last 11 years and that ended early for benefit was evaluated.

Results

A total of 25 RCTs were examined. More than 40% of the time-related primary end goals, including overall survival, were used to develop the methodology for evaluating effectiveness. The same end point that was intended for the final analysis was used to assess efficacy in 95% of the trials at the intermediate analysis. Approximately 3300 patients and events were saved across all investigations as a result of the early termination following the interim analysis. Over 78% of the RCTs that were published in the previous three years were used for registration.

Conclusion

It appears inappropriate to criticize the subpar quality of oncological trials, but regrettably, early termination creates additional issues. There is a market-driven aim, as evidenced by the relationship between reducing time and trial expenses and preserving patients. Only untruncated trials, in our opinion, can offer a complete degree of evidence that can be used to clinical practice without the need for additional confirmatory studies.

Keywords

anticancer drugs, EMEA, FDA, end point interim analysis, RCT

Summary

The study evaluates the role of interim analysis in randomized controlled trials (RCTs) for novel anticancer medications, particularly those terminated early for benefit.
It examines every published clinical study with interim analysis related to anticancer medications over the past 11 years that ended early for positive outcomes.
A total of 25 RCTs were reviewed, with over 40% utilizing time-related primary endpoints, such as overall survival, to assess effectiveness.
In 95% of the trials, the same endpoint intended for final analysis was used to evaluate efficacy during interim analysis.
Early termination due to interim analysis resulted in the saving of approximately 3300 patients and events across all studies.
More than 78% of RCTs published in the last three years contributed to registration processes.
While it is inappropriate to generally criticize the quality of oncological trials, early termination can lead to additional challenges.
There exists a market-driven objective linking reduced trial duration and costs to patient preservation.
The authors advocate that only untruncated trials can provide comprehensive evidence applicable to clinical practice without necessitating further confirmatory studies.